{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:25:04Z","timestamp":1767651904264,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.3816\/ccc.2002.n.010","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:05:30Z","timestamp":1221080730000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Eastern Cooperative Oncology Group Phase II Trial (E4296) of Oral 5-Fluorouracil and Eniluracil as a 28-Day Regimen in Metastatic Colorectal Cancer"],"prefix":"10.3816","volume":"2","author":[{"given":"John C.","family":"Marsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Cornfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"O'Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Al B.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2002.n.010_bib1","first-page":"2638","article-title":"Chemotherapy of large bowel cancer","volume":"50","author":"Davis","year":"1982","journal-title":"Cancer"},{"key":"10.3816\/CCC.2002.n.010_bib2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2125.1979.tb04651.x","article-title":"Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients","volume":"7","author":"Finch","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CCC.2002.n.010_bib3","first-page":"5405","article-title":"Enzymes of uracil catabolism in normal and neoplastic human tissues","volume":"45","author":"Naguib","year":"1985","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2002.n.010_bib4","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/0006-2952(93)90615-4","article-title":"5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo","volume":"46","author":"Spector","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CCC.2002.n.010_bib5","doi-asserted-by":"crossref","first-page":"11064","DOI":"10.1073\/pnas.90.23.11064","article-title":"5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil","volume":"90","author":"Baccanari","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CCC.2002.n.010_bib6","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.1999.17.8.2439","article-title":"Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors","volume":"17","author":"Ahmed","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib7","first-page":"1507","article-title":"5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma","volume":"54","author":"Cao","year":"1994","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2002.n.010_bib8","first-page":"245a","article-title":"A phase II trial of 7 days of oral 776C85 plus 5 days of 5-fluorouracil (5FU) in patients (pts) with metastatic colorectal cancer (M-CRC), a North Central Cancer Treatment Group study","volume":"19","author":"Goldberg","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib9","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.2000.18.15.2894","article-title":"Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer","volume":"18","author":"Mani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.2002.20.4.987","article-title":"Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer","volume":"20","author":"Rivera","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib11","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.2000.18.12.2378","article-title":"Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study","volume":"18","author":"Smith","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib12","first-page":"256a","article-title":"A multicenter, phase II trial of oral eniluracil plus 5-FU in patients with inoperable hepatocellular carcinoma","volume":"18","author":"Benson","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1023\/A:1011141530545","article-title":"A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer","volume":"17","author":"Knowling","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib14","first-page":"1239","article-title":"Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil","volume":"55","author":"Spector","year":"1995","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"10.3816\/CCC.2002.n.010_bib15","first-page":"21","article-title":"Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology","volume":"15","author":"Diasio","year":"2001","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CCC.2002.n.010_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF00662639","article-title":"Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alphafluoro- beta-alanine","volume":"81","author":"Okeda","year":"1990","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.3816\/CCC.2002.n.010_bib17","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2002.n.010_bib18","first-page":"41","article-title":"Capecitabine in colorectal cancer","volume":"15","author":"Marshall","year":"2001","journal-title":"Oncology (Huntingt)"},{"issue":"suppl 2","key":"10.3816\/CCC.2002.n.010_bib19","first-page":"49","article-title":"UFT in the treatment of colorectal and breast cancer","volume":"15","author":"Sun","year":"2001","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CCC.2002.n.010_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer","volume":"16","author":"Meta-analysis Group in Cancer","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation of incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CCC.2002.n.010_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2002.20.6.1519","article-title":"Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic\/advanced colorectal cancer","volume":"20","author":"Schilsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib24","first-page":"131a","article-title":"International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)","volume":"20","author":"Van Cutsem","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib25","first-page":"282a","article-title":"A phase II trial of a seven day regimen of oral 776C85 plus a five day regimen of oral 5-fluorouracil (5-FU) in untreated patients (pts) with metastatic colorectal cancer (M-CRC): a North Central Cancer Treatment Group study","volume":"17","author":"Goldberg","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib26","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/1097-0142(20010401)91:7<1256::AID-CNCR1126>3.0.CO;2-V","article-title":"Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma","volume":"91","author":"Meropol","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CCC.2002.n.010_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1023\/A:1008356522080","article-title":"A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer","volume":"11","author":"Schilsky","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jnci\/88.10.668","article-title":"Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer","volume":"88","author":"Hansen","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CCC.2002.n.010_bib29","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib30","first-page":"265a","article-title":"A phase III trial of Xeloda\u2122 (capecitabine) in previously untreated advanced\/metastatic colorectal cancer","volume":"18","author":"Cox","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2002.n.010_bib31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2002.n.010_bib32","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811705011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811705011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:01:32Z","timestamp":1761519692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811705011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S1533002811705011"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2002.n.010","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eastern Cooperative Oncology Group Phase II Trial (E4296) of Oral 5-Fluorouracil and Eniluracil as a 28-Day Regimen in Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2002.n.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}